Table 1.
Patients Baseline Characteristics of kidney transplant patients.
| Characteristics | Normal (n=10) | CAAMR (n=17) | CAMR (n=7) | p value |
|---|---|---|---|---|
| Age, year-mean ± SD | 36.6 ± 14.49 | 44.78 ± 15.46 | 41.47 ± 14.09 | 0.68 |
| Male sex- n (%) | 8 (80%) | 14(82.35%) | 6 (85.71%) | 0.99 |
| Donor (relative)-n (%) | 0 (0%) | 1 (5.88%) | 1 (14.29%) | 0.52 |
| Retransplantation-n (%) | 0 (0%) | 0 (0%) | 1 (14.29%) | 0.18 |
| Time posttransplant to biopsy, days- Median (Q1-Q3) | 606(545.75- 892.5) | 606(614.75- 2051.5) | 1932(735- 2099.5) | 0.29 |
| Biopsy times(n) | 1.2 ± 0.4 | 1.35 ± 0.58 | 1.43 ± 0.49 | 0.66 |
| Infections-n (%) | 3 (30%) | 5 (29.41%) | 2 (28.57%) | 0.99 |
| Diabetic nephropathy, (%) | 2 (20%) | 6 (35.29%) | 0 (0%) | 0.3 |
| Diabetes after transplantation-n (%) | 1 (10%) | 1 (5.88%) | 1 (14.29%) | 0.83 |
| HLA mismatch-mean ± SD | ||||
| HLA A/B mismatch | 3.33 ± 0.94 | 2.91 ± 0.95 | 2.71 ± 0.88 | 0.44 |
| HLA DR mismatch | 1.66 ± 0.47 | 1.75 ± 0.43 | 1.43 ± 0.73 | 0.49 |
| cPRA(%) | 66.2 ± 11.5 | 64.9 ± 13.6 | 64.6 ± 17.5 | 0.97 |
| PRA pretransplantation | 2 (20%) | 2 (11.76%) | 1 (14.29%) | 0.88 |
| Anti-HLA DSA at the time of biopsy-n (%) | 0 (0%) | 14(82.35%) | 5 (71.43%) | 0.03 |
| Class I | 0 (0%) | 0 (0%) | 1 (14.29%) | |
| Class II | 0 (0%) | 12 (70.59%) | 4 (57.14%) | |
| Class I+II | 0 (0%) | 2 (11.76%) | 0 (0%) | |
| Immunosuppressive therapy- n (%) | ||||
| CNI | 0.71 | |||
| FK-n (%) | 8 (80%) | 10 (58.82%) | 6 (85.71%) | |
| CsA-n (%) | 2 (20%) | 6 (35.29%) | 1(14.29%) | |
| Other-n (%) | 0 (0%) | 1(5.88%) | 0 (0%) | |
| MMF | 0.39 | |||
| Mythology-n (%) | 5 (50%) | 9 (52.94%) | 6 (85.71%) | |
| Myfortic-n (%) | 5 (50%) | 5 (29.41%) | 0 (0%) | |
| Other-n (%) | 0 (0%) | 3 (17.65%) | 1 (14.29%) | |
| Pred | ||||
| Prednisone-n (%) | 10 (100%) | 18 (100%) | 7 (100%) | 1 |
| Allograft loss-n (%) | 0 | 5 (29.41%) | 3 (42.86%) | 0.19 |
HLA, histocompatibility leukocyte antigen; cPRA, calculated panel reactive antibody; PRA, panel reactive antibody; DSA, donor-specific antibodies; CNI, Calcineurin inhibitor; FK, tacrolimus; CSA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; CAAMR, Chronic active antibody-mediated rejection; CAMR, chronic antibody-mediated rejection.